Forensic Implications of Kratom: Kratom Toxicity, Correlation with Mitragynine Concentrations, and Polypharmacy (original) (raw)

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

1. • Han C, Schmitt J, Gilliland KM. DARK classics in chemical neuroscience: kratom. ACS Chem Neurosci. 2020;11(23):3870. https://doi.org/10.1021/acschemneuro.9b00535. This article is a good review on the chemical properties, pharmacology, and use of kratom.
   Article CAS Google Scholar
2. Cinosi E, Martinotti G, Simonato P, Singh D, Demetrovics Z, Roman-Urrestarazu A, Bersani FS, Vicknasingam B, Piazzon G, Li JH, Yu WJ, Kapitány-Fövény M, Farkas J, Di Giannantonio M, Corazza O. Following “the roots” of kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western countries. Biomed Res Int. 2015;2015:968786. https://doi.org/10.1155/2015/968786.
   Article CAS PubMed PubMed Central Google Scholar
3. Eastlack SC, Cornett EM, Kaye AD. Kratom-pharmacology, clinical implications, and outlook: a comprehensive review. Pain Ther. 2020;9(1):55–69. https://doi.org/10.1007/s40122-020-00151-x.
   Article PubMed PubMed Central Google Scholar
4. Prozialeck WC, Lamar PC, Krupp M 2nd, Moon M, Phelps LE, Grundmann O. Kratom use within the context of the evolving opioid crisis and the COVID-19 pandemic in the United States. Front Pharmacol. 2021;26(12):729220. https://doi.org/10.3389/fphar.2021.729220.
   Article CAS Google Scholar
5. Grundmann O. Patterns of kratom use and health impact in the US-results from an online survey. Drug Alcohol Depend. 2017;1(176):63–70. https://doi.org/10.1016/j.drugalcdep.2017.03.007.
   Article Google Scholar
6. Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 2020;1(208):107849.
   Article Google Scholar
7. Smith KE, Dunn KE, Rogers JM, Garcia-Romeu A, Strickland JC, Epstein DH. Assessment of kratom use disorder and withdrawal among an online convenience sample of US adults. J Addict Med. 2022;16(6):666–70.
   Article PubMed PubMed Central Google Scholar
8. Brown PN, Lund JA, Murch SJ. A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: implications for products sold as kratom. J Ethnopharmacol. 2017;18(202):302–25. https://doi.org/10.1016/j.jep.2017.03.020.
   Article CAS Google Scholar
9. Sharma A, McCurdy CR. Assessing the therapeutic potential and toxicity of Mitragyna speciosa in opioid use disorder. Expert Opin Drug Metab Toxicol. 2021;17(3):255–7. https://doi.org/10.1080/17425255.2021.1853706.
   Article CAS PubMed Google Scholar
10. •• Kruegel AC, Uprety R, Grinnell SG, Langreck C, Pekarskaya EA, Le Rouzic V, Ansonoff M, Gassaway MM, Pintar JE, Pasternak GW, Javitch JA, Majumdar S, Sames D. 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Cent Sci. 2019;5(6):992–1001. https://doi.org/10.1021/acscentsci.9b00141. Demonstrating that 7-hydroxymitragynine is a metabolite of mitragynine and furthers our understanding of kratom’s effects.
    Article CAS PubMed PubMed Central Google Scholar
11. Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2018;134(Pt A):108–20. https://doi.org/10.1016/j.neuropharm.2017.08.026.
    Article CAS PubMed Google Scholar
12. León F, Obeng S, Mottinelli M, Chen Y, King TI, Berthold EC, Kamble SH, Restrepo LF, Patel A, Gamez-Jimenez LR, Lopera-Londoño C, Hiranita T, Sharma A, Hampson AJ, Canal CE, McMahon LR, McCurdy CR. Activity of Mitragyna speciosa (“kratom”) alkaloids at serotonin receptors. J Med Chem. 2021;64(18):13510–23.
    Article PubMed PubMed Central Google Scholar
13. Obeng S, Kamble SH, Reeves ME, Restrepo LF, Patel A, Behnke M, Chear NJ, Ramanathan S, Sharma A, León F, Hiranita T, Avery BA, McMahon LR, McCurdy CR. Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids. J Med Chem. 2020;63(1):433–9.
    Article CAS PubMed Google Scholar
14. •• Kamble SH, León F, King TI, Berthold EC, Lopera-Londoño C, Siva Rama Raju K, Hampson AJ, Sharma A, Avery BA, McMahon LR, McCurdy CR. Metabolism of a kratom alkaloid metabolite in human plasma increases its opioid potency and efficacy. ACS Pharmacol Transl Sci. 2020;3(6):1063–8. https://doi.org/10.1021/acsptsci.0c00075. This research of a mitragynine metabolite that is a potent MOR agonist could help explain kratom’s pharmacology and psychoactive properties.
    Article CAS PubMed PubMed Central Google Scholar
15. • Váradi A, Marrone GF, Palmer TC, Narayan A, Szabó MR, Le Rouzic V, Grinnell SG, Subrath JJ, Warner E, Kalra S, Hunkele A, Pagirsky J, Eans SO, Medina JM, Xu J, Pan YX, Borics A, Pasternak GW, McLaughlin JP, Majumdar S. Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with Mu agonism and delta antagonism, which do not recruit β-arrestin-2. J Med Chem. 2016;59(18):8381–97. https://doi.org/10.1021/acs.jmedchem.6b00748. An important paper on the MOR pharmacology of Mitragyna alkaloids.
    Article CAS PubMed PubMed Central Google Scholar
16. Wade P. Bentuangie Kratom Strains & Their Effects [Internet]. Kratom.org. 2022. [cited 29 November 2022] Available from: kratom.org/strains/bentuangie
17. Eggleston W, Stoppacher R, Suen K, Marraffa JM, Nelson LS. Kratom use and toxicities in the United States. Pharmacotherapy. 2019;39(7):775–7. https://doi.org/10.1002/phar.2280.
    Article PubMed Google Scholar
18. Leong Bin Abdullah MFI, Singh D. The adverse cardiovascular effects and cardiotoxicity of kratom (Mitragyna speciosa Korth.): a comprehensive review. Front Pharmacol. 2021;27(12):726003. https://doi.org/10.3389/fphar.2021.726003.
    Article CAS Google Scholar
19. Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm. 2009;66(9):825–33. https://doi.org/10.2146/ajhp070392.
    Article CAS PubMed Google Scholar
20. Smith KE, Lawson T. Prevalence and motivations for kratom use in a specimen of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017 Nov;1(180):340–8. https://doi.org/10.1016/j.drugalcdep.2017.08.034.
    Article Google Scholar
21. Weiss ST, Douglas HE. Treatment of kratom withdrawal and dependence with buprenorphine/naloxone: a case series and systematic literature review. J Addict Med. 2021;15(2):167–72. https://doi.org/10.1097/ADM.0000000000000721.
    Article PubMed Google Scholar
22. Broyan VR, Brar JK, Allgaier Student T, Allgaier JT. Long-term buprenorphine treatment for kratom use disorder: a case series. Subst Abus. 2022;43(1):763–6.
    Article CAS PubMed Google Scholar
23. Smith KE, Dunn KE, Epstein DH, Feldman JD, Garcia-Romeu A, Grundmann O, Henningfield JE, McCurdy CR, Rogers JM, Schriefer D, Singh D, Weiss ST. Need for clarity and context in case reports on kratom use, assessment, and intervention. Subst Abus. 2022;43(1):1221–4.
    Article PubMed Google Scholar
24. •• Papsun DM, Chan-Hosokawa A, Friederich L, Brower J, Graf K, Logan B. The trouble with kratom: analytical and interpretative issues involving mitragynine. J Anal Toxicol. 2019;43(8):615–29. https://doi.org/10.1093/jat/bkz064. This paper constitutes the largest dataset of mitragynine in forensic toxicology casework.
    Article CAS PubMed Google Scholar
25. Bourgine J, Garnier-Jardin C, Chrétien B, Le Boisselier R, Loilier M, Lelong-Boulouard V, et al. Fatal intoxication with kratom: a case report. Toxicologie Analytique et Clin. 2019;31:S36–7.
    Article Google Scholar
26. • Wang C, Walker AE. Fatal mitragynine-associated toxicity in Canada: a case report and review of the literature. Acad Forensic Pathology. 2019;8:340–6. Case report with elevated mitragynine blood concentration and mitragynine is primarily implicated
    Article Google Scholar
27. • Matson M, Schenk N. Fatality of 33-year-old man involving kratom toxicity. J Forensic Sci. 2019;64:1933–5. Case report with elevated mitragynine blood concentration and mitragynine is primarily implicated
    Article PubMed Google Scholar
28. • Mata DC, Andera KM. Case series: mitragynine blood and tissue concentrations in fatalities from 2017 to 2018 in Orange County, CA, USA. Forensic. Chemistry. 2020;17:100205. Case series of cases involving mitragynine with more detail
    CAS Google Scholar
29. •• Gershman K, Timm K, Frank M, Lampi L, Melamed J, Gerona R, et al. Deaths in Colorado attributed to kratom. New England J Med. 2019;380:97–8. Case series of cases involving mitragynine with more detail
    Article Google Scholar
30. • Behonick GS, Vu C, Czarnecki L, El-Ters M, Shanks KG. Two single-drug fatal intoxications by mitragynine. J Anal Toxicol. 2022;46(5):e110–4. https://doi.org/10.1093/jat/bkac016. Case report with elevated mitragynine blood concentration and mitragynine is listed in COD
    Article CAS PubMed Google Scholar
31. • Trakulsrichai S, Sathirakul K, Auparakkitanon S, Krongvorakul J, Sueajai J, Noumjad N, et al. Pharmacokinetics of mitragynine in man. Drug Des, Dev Ther. 2015;9:2421–9. An important paper on one of the few pharmacokinetic studies of kratom use in humans
    CAS Google Scholar
32. Grundmann O. Patterns of kratom use and health impact in the US-results from an online survey. Drug Alcohol Depend. 2017;1(176):63–70.
    Article Google Scholar
33. • Tanna RS, Nguyen JT, Hadi DL, Manwill PK, Flores-Bocanegra L, Layton ME, et al. Clinical pharmacokinetic assessment of Kratom (Mitragyna Speciosa), a botanical product with opioid-like effects, in healthy adult participants. Pharmaceutics. 2022;14:620. An important paper on one of the few pharmacokinetic studies of kratom use in humans
    Article CAS PubMed PubMed Central Google Scholar
34. • Chadchoy P, Sinchai T. The relationship between Mitragynine blood concentrations and death in Thailand. Interdiscip Res Rev. 2020;15:18–21. An important paper reporting blood mitragynine concentrations in non-pathological causes of death
    Google Scholar
35. Brower J. Mitragynine-only deaths in North Carolina. In: Society of Forensic Toxicologists Annual Conference. Society of Forensic Toxicologists; 2022.
    Google Scholar
36. Karinen R, Fosen JT, Rodge S, Vindenes V. An accidental poisoning with mitragynine. Forensic Sci Int. 2014;245:e29–232.
    Article CAS PubMed Google Scholar
37. O’Malley Olsen E, O’Donnell J, Mattson CL, Schier JG, Wilson N. Unintentional drug overdose deaths with kratom detected – 27 states, July 2016-December 2017. Morbid Mortal Weekly Rep. 2019;68(14):326–7.
    Article Google Scholar
38. •• Schmitt J, Bingham K, Knight L. Kratom-associated fatalities in northern Nevada – what mitragynine level is fatal? Am J Forensic Med Pathol. 2021;42(4):341–9. Case series of cases involving mitragynine with more detail
    Article PubMed Google Scholar
39. Basiliere S, Kerrigan S. Temperature and pH-dependent stability of mitragyna alkaloids. J Anal Toxicol. 2020;44:314–24. https://doi.org/10.1093/jat/bkz103.
    Article CAS PubMed Google Scholar
40. Basiliere S, Brower J, Winecker R, Friederich L, Kerrigan S. Identification of five mitragyna alkaloids in blood and tissues using liquid chromatography-quadrupole/time-of-flight mass spectrometry. Forensic Toxicol. 2020;38:420–35. https://doi.org/10.1007/s11419-020-00537-8.
    Article CAS Google Scholar
41. Nacca N, Schult RF, Li L, Spink DC, Ginsberg G, Navarette K, et al. Kratom adulterated with phenylethylamine and associated intracerebral hemorrhage: linking toxicologists and public health officials to identify dangerous adulterants. J Med Toxicol: Official J Am College Med Toxicol. 2020;16:71–4.
    Article Google Scholar
42. Hoonwijit U, Waithum K, Tansrisawad N. Comparison of mitragynine stability in human blood in common blood collection tubes. Chulalongkorn Med J. 2020;64:439447.
    Google Scholar
43. Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, mitragyna speciosa. Chem Pharm Bull. 2004;52(8):916–28.
    Article CAS Google Scholar
44. Hanapi NA, Chear NJY, Azizi J, Yusof SR. Kratom alkaloids: interactions with enzymes. Front Pharmacol. 2021;17(12):751656.
    Article Google Scholar
45. Henningfield JE, Rodricks JV, Manguson AM, Huestis MA. Respiratory effects of oral mitragynine and oxycodone in a rodent model. Psychopharmacology. 2022;239(12):3793–804.
    Article CAS PubMed PubMed Central Google Scholar
46. Kapp F, Maurer H, Auwärter V, Winkemann M, Hermanns-Clausen M. Intrahepatic cholestasis following abuse of powdered kratom (mitragyna speciosa). J Med Toxicol. 2011;7:227–31.
    Article PubMed PubMed Central Google Scholar
47. Nelsen JL, Lapoint J, Hodgman MJ. Seizure and coma following kratom (mitragynine speciosa korth) exposure. J Med Toxicol. 2020;6:424–6.
    Article Google Scholar
48. Dorman C, Wong M, Khan A. Cholestatic hepatitis from prolonged kratom use: a case report. Hepatology. 2015;61(3):1086–7.
    Article PubMed Google Scholar
49. Tayabeli K, Bolzon C, Foster P, Patel J, Kalim MO. Kratom: a dangerous player in the opioid crisis. J Community Hosp Intern Med Perspect. 2018;8(3):107–10.
    Article Google Scholar
50. Afzal H, Esang M, Rahman S. A case of kratom-induced seizures. Cureus. 2020;12:e6588.
    PubMed PubMed Central Google Scholar
51. Ahmad J, Odin JA, Hayashi PH, Fontana RJ, Conjeevaram H, Avula B, et al. Liver injury associated with kratom, a popular opioid-like product: experience from the U.S. drug induced liver injury network and a review of the literature. Drug Alcohol Depend. 2021;1(218):108426. https://doi.org/10.1016/j.drugalcdep.2020.108426.
    Article CAS Google Scholar
52. Schimmel J, Dart RC. Kratom (Mitragyna Speciosa) liver injury: a comprehensive review. Drugs. 2020;80:263–83.
    Article CAS PubMed Google Scholar
53. Singh D, Narayanan S, Müller CP, Swogger MT, Rahim AA, Leong Bin Abdullah MFI, et al. Severity of kratom (Mitragyna speciosa Korth.) psychological withdrawal symptoms. J Psychoact Drugs. 2018;50:445–50.
    Article Google Scholar
54. Overbeek DL, Abraham J, Munzer BW. Kratom (Mitragynine) ingestion requiring naloxone reversal. Clin Pract Cases Emerg Med. 2019;3:24–6.
    Article PubMed PubMed Central Google Scholar
55. Stanciu CN, Gnanasegaram SA, Ahmed S, Penders T. Kratom withdrawal: a systematic review with case series. J Psychoact Drugs. 2019;51:12–8.
    Article Google Scholar
56. Assangkornchai S, Muekthong A, Sam-Angsri N, Pattanasttayawong U. The use of mitragynine speciosa (“krathom”), an addictive plant in Thailand. Subst Use Misuse. 2007;24(14):2145–57.
    Article Google Scholar
57. McWhirter L, Morris S. A case report of inpatient detoxification after kratom (mitragyna speciosa) dependence. Eur Addict Res. 2010;16(4):229–31.
    Article PubMed Google Scholar
58. Cumpston KL, Carter M, Wills BK. Clinical outcomes after Kratom exposures: a poison center case series. Am J Emerg Med. 2018;36:166–8.
    Article PubMed Google Scholar
59. Post S, Spiller HA, Chounthirath T, Smith GA. Kratom exposures reported to United States poison control centers: 2011-2017. Clin Toxicol (Phil). 2019;57:847–54.
    Article CAS Google Scholar
60. •• Corkery JM, Streete P, Claridge H, Goodair C, Papanti D, Orsolini L, et al. Characteristics of deaths associated with kratom use. J Psychopharmacol (Oxford, England). 2019;33:1102–23. [High level review of mitragynine involvement in fatalities]
    Article Google Scholar

Download references